Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.

Cancer letters - 18 Sept 2007

Panani Anna D

Abstract excerpt

Chronic myeloproliferative disorders (CMPD) are clonal disorders of the hematopoietic stem cell. The myeloid lineage shows increased proliferation with effective maturation, while peripheral leukocytosis, thrombocytosis or elevated red blood cell mass are found. In Philadelphia negative CMPD recurrent cytogenetic abnormalities occur, but no specific abnormality has been defined to date. The spectrum of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosomes, Human, Pair 8
Share to Cytogenetics
Share to Hematopoietic Stem Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Primary Myelofibrosis

Share to Thrombocythemia, Essential

Share to Translocation, Genetic

Source

Identifiers

PMID: 17383090
DOI: 10.1016/j.canlet.2007.02.009

Genes

FGFR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.PMID 17383090Read ↗

The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markersSemantic proximity Read ↗

Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs).Semantic proximity Read ↗

Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.Semantic proximity Read ↗

Philadelphia Chromosome–Negative Chronic Myeloproliferative DiseaseSemantic proximity Read ↗

Philadelphia Chromosome–Negative Myeloproliferative Disorders: Biology and TreatmentSemantic proximity Read ↗

Stem cell defects in Philadelphia chromosome negative chronic myeloproliferative disorders: a phenotypic and molecular puzzle?Semantic proximity Read ↗

Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review).Semantic proximity Read ↗

Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders.Semantic proximity Read ↗

The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.Semantic proximity Read ↗

Myeloproliferative neoplasms: Current molecular biology and genetics.Semantic proximity Read ↗

Conventional cytogenetics in myelofibrosis: literature review and discussionSemantic proximity Read ↗

Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.